苏州迪新宸科生物科技

Suzhou Dixin Chenke Biotechnology is a Chinese biotechnology company specializing in the development of mRNA-based therapeutics and advanced delivery systems. The company leverages its proprietary lipid nanoparticle (LNP) platform, known as D-LNP, to design vaccines and treatments for infectious diseases and oncology. Dixin Chenke focuses on optimizing the stability and tissue-targeting capabilities of mRNA molecules to improve therapeutic efficacy and safety profiles. Their pipeline includes several candidates in the discovery and pre-clinical stages, including vaccines for COVID-19 and influenza. The company is headquartered in the Suzhou Industrial Park, benefiting from the region's robust life sciences ecosystem.